Denali Therapeutics Inc. (DNLI) financial statements (2020 and earlier)
Company profile
| Business Address |
161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO, CA 94080 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 479 | 464 | ||
| Cash and cash equivalents | 83 | 77 | ||
| Short-term investments | 397 | 387 | ||
| Receivables | 1 | |||
| Prepaid expense | 1 | |||
| Other undisclosed current assets | 15 | 14 | ||
| Total current assets: | 494 | 481 | ||
| Noncurrent Assets | ||||
| Operating lease, right-of-use asset | 34 | ✕ | ||
| Property, plant and equipment | 47 | 25 | ||
| Long-term investments and receivables | 24 | 148 | ||
| Long-term investments | 24 | 148 | ||
| Other noncurrent assets | 3 | 8 | ||
| Total noncurrent assets: | 109 | 181 | ||
| TOTAL ASSETS: | 603 | 662 | ||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 25 | 20 | ||
| Accounts payable | 2 | 2 | ||
| Accrued liabilities | 15 | 9 | ||
| Employee-related liabilities | 8 | 10 | ||
| Deferred revenue | 18 | ✕ | ||
| Deferred rent credit | 1 | |||
| Contract with customer, liability | ✕ | 11 | ||
| Other liabilities | 3 | 0 | ||
| Total current liabilities: | 47 | 33 | ||
| Noncurrent Liabilities | ||||
| Long-term debt and lease obligation | 70 | |||
| Operating lease, liability | 70 | ✕ | ||
| Liabilities, other than long-term debt | 48 | 82 | ||
| Deferred revenue | 48 | ✕ | ||
| Contract with customer, liability | ✕ | 57 | ||
| Deferred rent credit | 25 | |||
| Other liabilities | 0 | 0 | ||
| Total noncurrent liabilities: | 118 | 82 | ||
| Total liabilities: | 165 | 115 | ||
| Stockholders' equity | ||||
| Stockholders' equity attributable to parent | 438 | 547 | ||
| Common stock | 1 | 1 | ||
| Additional paid in capital | 808 | 774 | ||
| Accumulated other comprehensive income (loss) | 1 | (1) | ||
| Accumulated deficit | (372) | (228) | ||
| Total stockholders' equity: | 438 | 547 | ||
| TOTAL LIABILITIES AND EQUITY: | 603 | 662 | ||
Income statement (P&L) ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | ||
|---|---|---|---|
| Gross profit: | 148 | 129 | |
| Operating expenses | (228) | (176) | |
| Operating loss: | (81) | (46) | |
| Nonoperating income | 14 | 10 | |
| Investment income, nonoperating | 2 | 3 | |
| Loss from continuing operations before income taxes: | (66) | (36) | |
| Income tax benefit | 0 | ||
| Net loss available to common stockholders, diluted: | (66) | (36) | |
Comprehensive Income ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | ||
|---|---|---|---|
| Net loss: | (66) | (36) | |
| Comprehensive loss: | (66) | (36) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 2 | (0) | |
| Comprehensive loss, net of tax, attributable to parent: | (64) | (37) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.